Analyzing Abbott Laboratories’s Unusual Options Activity
Abbott Laboratories (NYSE:ABT) shares experienced unusual options activity on Friday. The stock price moved up to $120.17 following the option alert.
Morgan Stanley Maintains Overweight on Abbott Laboratories, Raises Price Target to $136
Morgan Stanley analyst Cecilia Furlong maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $126 to $136.
Credit Suisse Maintains Outperform on Abbott Laboratories, Raises Price Target to $130
Credit Suisse analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $120 to $130.
Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $128
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $116 to $128.
Unusual Options Activity Insight: Abbott Laboratories
Abbott Laboratories (NYSE:ABT) shares experienced unusual options activity on Wednesday. The stock price moved down to $117.92 following the option alert.
Earnings Preview: Abbott Laboratories
Abbott Laboratories (NYSE:ABT) announces its next round of earnings this Thursday, July 22. Here is Benzinga's everything-that-matters guide for this Thursday's Q2 earnings announcement.
SVB Leerink Maintains Market Perform on Abbott Laboratories, Raises Price Target to $128
SVB Leerink analyst Danielle Antalffy maintains Abbott Laboratories (NYSE:ABT) with a Market Perform and raises the price target from $115 to $128.
Analyzing Abbott Laboratories’s Unusual Options Activity
Abbott Laboratories (NYSE:ABT) shares experienced unusual options activity on Monday. The stock price moved up to $119.12 following the option alert.
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.